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Case ReportLiver transplant from a donor with occult HEV infection
induced chronic hepatitis and cirrhosis in the recipient
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Rheumatology, Section Hepatology, University Medicine Leipzig, GermanyAbstract: Acute hepatitis E virus (HEV) infection is a self-limiting we reported the ﬁrst reactivation of a HEV infection in an acute
symptomatic or asymptomatic disease. However, as recently
observed, it can manifest itself as chronic hepatitis in patients
receiving solid organ transplants as well as in patients with HIV
infection or severe hematologic disorders.
Here, we describe the clinical course of a 73-year-old male
patient in whom HEV transmission occurred after receiving a
HEV-infected liver from a donor with occult HEV infection,
whereby the patient had tested negative for HEV RNA and anti-
HEV antibodies shortly before explantation.
Anti-HEV IgG, IgM, and HEV RNA were detected in the ﬁrst
tested serum sample of the liver recipient obtained 150 days after
liver transplantation and remained positive (earlier samples after
OLT were not available). Liver cirrhosis developed within
15 months and the patient died of septic shock. Based on phylo-
genetic analyses of the donor and recipient’s HEV strains, we
were able to prove that the occult HEV infection was transmitted
via the graft.
 2011 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
Hepatitis E virus (HEV) belongs to the family of Hepeviridae [1]
and is the sole member of the genus Hepevirus. HEV is subdi-
vided into the genotypes 1–4. Sporadic and epidemic outbreaks
in developing countries are mainly caused by genotype 1 and 2
strains. The other genotypes are considered as causative agents
of sporadic indigenous cases in industrialized countries [2–4].
HEV infection is characterized by an acute self-limiting course
in immunocompetent patients, but chronic HEV infections have
been described in solid-organ transplant patients [5]. Recently,Journal of Hepatology 20
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 These authors contributed equally to this work.lymphoblastic leukemia patient after allogeneic stem cell trans-
plantation [6]. The CD4+ lymphocyte count seemed to be a mar-
ker for the successful clearance of HEV by the cellular immune
response since the number of this lymphocyte subset was found
to be signiﬁcantly reduced in patients with lasting viremia [7].
Here, we report for the ﬁrst time HEV transmission via an
infected donor liver leading to chronic HEV infection and cirrho-
sis development in a German patient after orthotopic liver trans-
plantation (OLT).Case report
We describe the case of a 73-year-old male patient with a
30-year history of elevated liver enzymes. A diagnosis of non-
alcoholic fatty liver disease-induced cirrhosis was made in 2001
due to hyperlipidemia, type 2 insulin-dependent diabetes and
moderate adipositas. Other causes such as chronic viral hepatitis,
autoimmune, or hereditary liver disease could be excluded.
In August 2008, a multilocular hepatocellular carcinoma
(HCC) (three nodules, maximum size 3 cm) was diagnosed during
a routine computed tomography (CT) scan. Hepatitis B or C virus
infection was excluded but markers for previous varizella zoster
virus, cytomegalovirus (CMV), and Epstein–Barr virus (EBV)
infections were detected by standard serological assays prior to
OLT. Transplantation was performed without complications in
December 2008. To our knowledge, no blood transfusion was per-
formed within this period. The donor was a 65-year-old male
patient who had died of a heart attack. In addition to cardiovas-
cular disease, IDDM, and hyperlipoproteinemia were reported. At
the point of death, ALT values were four times the upper limit of
normal (ULN). No information on the levels of liver enzymes in
the preceding months/period was available. To our knowledge,
no blood transfusion was performed in the 3-month period
before transplantation. Histological assessment of the liver allo-
graft showed mild fatty liver changes but no signs of chronic hep-
atitis or ﬁbrotic alterations (Fig. 1A).
After OLT, liver enzymes increased temporarily, most likely
due to a reperfusion injury effect, but returned to normal levels
within a week. The immunosuppressive regimen consisted of
prednisolone (Merck, starting 1 mg/kg, tapering), tacrolimus12 vol. 56 j 500–502
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Fig. 1. Histologic assessment of the liver tissue before and after OLT and CT scan after OLT. (A) The liver tissue of the donor revealed absence of signiﬁcant signs of
chronic hepatitis but vesicular fatty liver disease was diagnosed. (B) Second biopsy. One hundred and ﬁfty days after OLT, chronic inﬂammation with portal and interface
hepatitis was described which was interpreted as an acute rejection. (C) Third biopsy. Three hundred and forty seven days after OLT, persistence of chronic hepatitis was
associated with portal and septal bridging signs of ﬁbrosis. (D) CT scan performed 1 year after liver transplantation revealed signs of portal hypertension including ascites,
splenomegaly and gastric varices compatible with decompensated liver cirrhosis.
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Fig. 2. Course of ALT, bilirubin and HEV RNA levels in a liver transplant
recipient with chronic HEV infection leading to liver cirrhosis within one
year. Immunosuppressive regimen was started immediately after OLT consisting
of prednisolone (reduction scheme) plus tacrolimus (4 mg/day) and rapamycin
(4 mg/day) (dark blue bars). After steroid tapering, maintenance immunosup-
pressive regimen with tacrolimus plus rapamycin was administered (light blue
bars). Intravenous high-dose methylprednisone bolus therapy (500 mg/day for
5 days) which was given for suspected acute rejection episodes are depicted in
black–white boxes. ALT and bilirubin values are given as x-fold the upper limit of
normal (ULN) (normal range of ALT 45 IU/L, and bilirubin 1.1 mg/dl). Positive
anti-HEV IgG/M results were obtained on days 150 and 420 after OLT but were
found to be negative at the time of transplantation.
JOURNAL OF HEPATOLOGY(Prograf, Astellas), and rapamycin (Sirolimus, Wyeth). Thirty-
seven days after transplantation, alanine aminotransferase
(ALT), aspartate aminotransferase (AST), and alkaline phospha-
tase levels (163 UL) became elevated (Fig. 2). Liver biopsy was
performed in February 2009 and revealed mild fatty liver degen-
eration without evidence of acute or chronic hepatitis or an acute
rejection episode (not shown). Weekly tests for CMV and EBV
DNA remained negative. In May 2009 (150 days after OLT),
another liver biopsy was performed due to increasing ALT levels
up to >5 times the ULN. At this stage, chronic inﬂammation with
portal and interface hepatitis potentially associated with acute
rejection could be observed (Fig. 1B) and intravenous steroid
bolus therapy (methylprednisolone, Urbasone, Sanoﬁ Aventis,
500 mg/day for 5 days) was started because of a suspected rejec-
tion episode. This resulted in a prompt decrease in liver enzymes.
Immunosuppressive regimen was continued with tacrolimus and
rapamycin. In November 2009 (333 days after OLT), the patient
presented with edema of the lower limb. Liver cirrhosis was diag-
nosed by ultrasound and CT scan showing an irregular liver sur-
face and a hypertrophy of the lobus caudatus (Fig. 1D). Liver
biopsy (347 days after OLT) revealed advanced (stages 3–4) ﬁbro-
sis (Fig. 1C).
In February 2010, liver disease decompensated as indicated by
ascites (CRP 8.7 mg/dl (normal <0.5 mg/dl), creatinine 1.4 mg/dl,
bilirubin 4.6 mg/dl, AST 154 U/L, ALT 148 U/L, AP 174 U/L, cGT
77 U/L, Hb11 g/dl, WBC 3.6/nl, TPZ 51%). The patient died in Feb-
ruary 2010 from septic shock probably due to a panenterocolitis
(as suspected from the CT scan). Escherichia coli bacteria were
found in blood and ascites cultures.Results
HEV diagnosis, detection of HEV in donor tissue
In February 2010, the markers for HEV infection, anti-HEV IgM/
IgG antibodies, were detected for the ﬁrst time by recomWell
ELISA (based on HEV genotype 1 antigens) and conﬁrmed by rec-
omBlot (based on HEV genotypes 1 and 3 antigens), both Mikro-
gen, Germany, and HEV RNA in serum by RT-PCR [8]. Anti-HEV
IgM/IgG antibodies and HEV RNA were also detected in a stored
serum sample from May 2009 (150 days after OLT). Serum sam-
ples from the period between OLT and day 150 were not available
and could not be tested for HEV serum markers. However, HEV
serology and HEV RNA were negative in samples obtained beforeJournal of Hepatology 201OLT in December 2008 suggesting that HEV infection occurred
during or after OLT. We also retrospectively examined pre-mortal
blood (obtained 1 day before explantation of the graft) and liver
tissue from the donor (obtained during explantation). Antibody
screening and RT-PCR of the donor serum sample were negative
but, surprisingly, HEV RNA was detected in high concentrations
in liver tissue of the donor. The 95% detection limit of the RT-PCR
was determined by probit analysis at approximately 2000 copies/
ml serum. Cross-binding and unspeciﬁc ampliﬁcation were not
observed for all other herpes and hepatitis virus genomes. The
sequence data of a partial fragment of the ORF3 region (161 base
pairs) of both serum- and tissue-derived HEV strains from the
recipient and the donor belonged to genotype 3 (Fig. 3). Both
sequences are identical whereas the identity rate between proto-
types of GT1 to GT4 is approximately 73% and approximately 83%2 vol. 56 j 500–502 501
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Fig. 3. Phylogentic tree constructed from patient and prototype HEV
sequences. HEV nucleotide sequences were aligned to construct a phylogenetic
tree using the neighbor-joining method. A rooted phylogram is shown, with an
avian HEV strain as outlier. The branch length is proportional to evolutionary
distance (scale bar). Results of bootstrap analysis (1000 replicates) are indicated
at the nodes of the tree. Accession Numbers given in brackets indicate prototype
strains from Genbank. The HEV_GT3_PC is obtained from a patient with a chronic
HEV infection after stem cell transplantation [6] and serves as positive control in
our PCR reactions.
Case Reportamong different genotype 3 sequences (not shown). By sequenc-
ing an additional fragment within ORF1 [9], the HEV subgenotype
3e was identiﬁed. Again, the sequence data obtained from serum
and liver tissue were concordant.
These data strongly suggest transmission via the transplanted
allograft. To validate these results repeated RNA extractions and
ampliﬁcations were performed and all conﬁrmed our initial
results. Possible contaminations of the PCRs could be almost cer-
tainly excluded because no other HEV RNA positive samples were
handled at this time in our laboratory. Additionally the donor-
recipient HEV RNA strain showed signiﬁcant nucleotide diver-
gence as compared to the positive control sample, which was
used in all PCRs, thereby excluding any contamination or sample
mix-up.Discussion
This clinical course convincingly demonstrates that HEV can per-
sist in liver tissue without serological evidence for HEV infection.
A rather low-level HEV carrier state may be responsible for the
lack of an anti-HEV response, but scant sensitivity of the current
anti-HEV assays also has to be considered as a possible cause.
Furthermore, based on phylogenetic analyses of the donor and
recipient’s HEV strains, we were able to prove that the occult HEV
infection was transmitted via the graft to an HEV seronegative
liver transplant recipient.
From HEV prevalence studies in wild boar [10] it became evi-
dent that a signiﬁcant proportion of viremic animals do not show
an anti-HEV antibody response. Thus, overall anti-HEV seroprev-
alence was approximately 25–30% whereas HEV RNA was found
to be positive in up to 68% of the animals. Furthermore, HEV
RNA was exclusively detected in the bile in a signiﬁcant propor-
tion of boars, supporting the existence of an occult HEV carrier
state. Legrand-Abranevel recently reported a high ratio of HEV
infections in solid organ transplant recipients. However, none of
those patients tested positive for HEV antibodies before OLT, sug-
gesting a greater likelihood of de novo infections than HEV reacti-
vations [11].
Immunosuppressive treatment inﬂuenced the rapid clinical
course of chronic HEV infection. The ﬁrst therapeutic successes
with pegylated interferon and especially ribavirin monotherapy502 Journal of Hepatology 201were recently achieved in transplant patients with chronic hepa-
titis E [12–15]. As clearance of the virus depends on the immune
status of the patient, reducing the immunosuppressive therapy is
generally recommended.
In conclusion, this is the ﬁrst report of HEV transmission via
an infected organ from a donor with occult HEV infection leading
to chronic HEV infection in a liver transplant recipient. HEV
might persist in the liver tissue and bile of patients without
any serologic evidence of infection. These ﬁndings may have
implications for future HEV screening strategies. Controlled stud-
ies are required to establish recommendations for the manage-
ment of patients with chronic HEV infection.Conﬂict of interest
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